SYMBIOTEC PHARMALAB LIMITED

Scale -

Revenue is 869 Rs Cr; Annual Growth is 16 %; Continuous Growth over 3 years; 5 Year CAGR is 10 %
Ebitda is 241 Rs Cr; Annual Growth is 17 %; Continuous Growth over 3 years; 5 Year CAGR is 16 %

PBT is 17.53 Rs Cr; Continuous Decline over 3 years
Quarterly Profit is 14.06 Rs Cr; Continuous Decline over 3 Quarters

Profitability -

PBDIT Margin is 27.72 %; Continuous Growth over 3 years

PAT Margin is 12.64 %; Continuous Decline over 3 years
Quarterly Ebitda Margin is 21 %; Continuous Decline over 3 Quarters
Quarterly Profit margin is 6 %; Continuous Decline over 3 Quarters

Return -

ROE is 9.55 %; Continuous Decline over 3 years; 5 Year CAGR is -17 %

Efficiency -

Inventory Turnover Ratio is 3.49; Annual Growth is 38 %; Continuous Growth over 3 years
Operating cash flow is 175 Rs Cr; Annual Growth is 269 %

Current Ratio is 0.92; Continuous Decline over 3 years; in Bottom Quartile; 5 Year CAGR is -20 %
Quick Ratio is 0.47; in Bottom Quartile

Solvancy -

Debt/Equity is 0.34; Annual Decline is -48 %
Long term Debt is 68.41 Rs Cr; Annual Decline is -73 %; 5 Year CAGR is -41 %

Contingent Liabilities is 100 Rs Cr; Annual Growth is 170 %
Total Debt is 388 Rs Cr; in Top Quartile; 5 Year CAGR is 25 %

Quality -

Operating cashflow/ebitda is 72 %; Annual Growth is 216 %; 5 Year CAGR is -17 %
Operating cashflow/PAT is 159 %; Annual Growth is 226 %; in Top Quartile
Exceptional Items/PBT is -6 %; in Bottom Quartile

Current Tax/PAT is 54 %; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 33 %
Other Expenses/Total Expenses is 23 %; Continuous Growth over 3 years
Change in Inventories/Total Expenses is 2 %; in Top Quartile

Quarterly Results- overall

Annual Results- Scale

Annual Results- Liquidity

Annual Results- Profitability/Return

Annual Results- Valuation

External Ecosystem

Sector

Major Subsidiaries/Associates

Key Clients

Products

Products

Product details

Operations

Capacity/ Production

Key Facilities

Key Certifications

Raw materials

Search: